

CURRICULUM VITAE

Kaylen Mark Silverberg, M.D.

PLACE OF BIRTH: Dallas, Texas

EDUCATION:

College:	Vanderbilt University, Nashville, Tennessee B.S. Molecular Biology and Business Administration	1981
Medical School:	Baylor College of Medicine, Houston, TX, M.D.	1984
Internship/Residency:	Vanderbilt University Medical Center Department of Obstetrics/Gynecology Nashville, TN Chief Resident	1985-1989 1989
Fellowship:	The University of Texas Health Science Center Reproductive Endocrinology and Infertility San Antonio, TX	1989-1991

BOARD CERTIFICATION:

American Board of Obstetrics and Gynecology-Board Certified Annual Recertification since 2002	1992
Subspecialty Board of Reproductive Endocrinology-Board Certified Annual Recertification since 2002	1994

MEDICAL LICENSES:

Texas, 1986; Tennessee, 1987

ACADEMIC APPOINTMENTS:

Clinical Assistant Professor, Department of Obstetrics & Gynecology Division of Reproductive Endocrinology/Infertility The University of Texas Dell Medical School at Austin	2010-2015
Clinical Associate Professor, Department of Obstetrics & Gynecology The University of Texas Medical Branch at Galveston	1999-2009

Clinical Assistant Professor, Department of Obstetrics & Gynecology
The University of Texas Health Science Center
at San Antonio, San Antonio, Texas 1994-1999

Assistant Professor, Department of Obstetrics & Gynecology
The University of Texas Health Science Center
at San Antonio, San Antonio, Texas 1989-1994

CURRENT POSITIONS:

Medical Director, Texas Fertility Center 1997-Present
Medical Director, Ovation-Austin 2015-Present
Laboratory Director, San Antonio IVF 2014-Present
Medical Director, Austin IVF 2004-2015
Laboratory Director, Austin IVF 2004-2015
Venture Partner, Spindletop Healthcare Capital 2011-Present
Strategic Advisory Council, Sante Ventures 2013-Present
Board of Directors, Society for Assisted Reproductive Technology 2014-2016
President, Governing Board St. David's North Austin Surgical Center 2013-Present
Medical Executive Committee, St. David's North Austin Surgical Center 2012-Present
Board of Directors, Austin Fertility Surgery Center 2016-Present
Managing Partner – VSH Real Estate 2008-Present

BOARD APPOINTMENTS:

Board of Directors – Ovation Fertility 2015-Present
Board of Directors – Ovation Genetics 2016-Present
TEXPAC Board of Directors 2011-2015
Good Start Genetics – Medical Advisory Board 2010-2017
emdSerono, Inc – Medical Advisory Board 2007-Present
Allergan Pharmaceuticals – Medical Advisory Board 2010-2017
Texas Medical Accelerator – Medical Advisory Board 2012-2016
Teva Pharmaceuticals – Medical Advisory Board 2013-2015
Extend Fertility, Inc. Medical Advisory Board 2004-2009

EXTRA MURAL APPOINTMENTS:

CostDoctor, Inc. 1999-2003
Founder
Chief Executive Officer

“Beyond the Birds and Bees” weekly Radio Show 2010-2011
Co-Host
Co-Producer

Society for Assisted Reproductive Technology	1989-Present
Secretary/Treasurer	1999-2001
Board of Directors	2014-2016
	1998-2001
	1995-1997
International Committee	1997-2001
Research Committee	1992-2001
Chairman	1999
Finance Committee	1999-2001
American Society for Reproductive Medicine	1987-Present
Continuing Medical Education Committee	1997-1999
Coding Committee	2006-2008
Society for Reproductive Endocrinology & Infertility	1989-Present
Nominating Committee	1999
Pacific Coast Fertility Society	1989-Present
Board of Directors	2000-2002
Treasurer	2001-2002
Program Chairman, Annual Meeting	1998
Southwest Fertility Forum	
Annual Meeting, Program Chairman	2014
Annual Meeting, Program Chairman	2009
Texas Society for Assisted Reproductive Technology	
Annual Meeting Program Chairman	2005
Annual Meeting Program Co-Chairman	2002
Annual Meeting Program Co-Chairman	2001
Annual Meeting Program Co-Chairman	1998
Annual Meeting Program Co-Chairman	1996
Annual Meeting Program Chairman	1994
American Fertility Association	
National Medical Advisory Board	2000-2006
Resolve	
National Physician Advisory Board	1997-2000
Southwest Airlines- Fertility Consultant	1997-Present
EMD Serono, Inc. – Advisor	2003-Present
Allergan Pharmaceuticals – Advisor, Consultant	2010-2016

Counsyl Corporation – Advisor	2009-2011
Genzyme Corporation – Consultant	2003-2006
	2008-2011
Gerson Lehrman Group – Consultant	2002-Present
The Roundtable Group – Consultant	2010-Present
Guidepoint Global – Consultant	2013-Present
Society of Industry Leaders – Consultant	2007-Present
Livestrong-Lance Armstrong Foundation – Advisor	2010-2015
Komen Foundation – Doctors for the Cure	2012-Present
Patton Surgical – Advisor	2006-2011
United Health Resource Network – Consultant	2003-2010
Columbia Labs – Physician Advisory Board	2008-2010
KV Pharmaceuticals – Consultant	2008-2009
Baxter Biosurgery, Inc. – Consultant	2006-2008
Editorial Board, Time Life Medical Video Productions	1995-1997
Director, In Vitro Fertilization Program and Laboratories, The University of Texas Health Science Center at San Antonio	1990-1994

HOSPITAL APPOINTMENTS:

North Austin Medical Center, Austin, TX	1995-Present
Seton Hospital, Austin, TX	1994-Present
St. David's Hospital, Austin, TX	1994-Present
Seton Northwest, Austin, TX	1994-Present
South Austin Hospital, Austin, TX	1994-Present
Brackenridge Hospital, Austin, TX	1994-Present
Round Rock Medical Center, Round Rock, TX	2006-Present
North Austin Surgery Center, Austin, TX	2005-Present
Methodist Stone Oak Hospital, San Antonio, TX	2014-Present
Austin Fertility Surgery Center, Austin, TX	2016-Present

HONORS AND AWARDS:

Star Award-American Society for Reproductive Medicine	2013-Present
Certificate of Appreciation-Department of the U.S.Army	2012
ASRM Service Award	2011
Austin Healthcare Heroes Nominee	2009
Finalist, Distinguished Surgeon of the Year – Association of Operating Room Nurses, Austin Chapter	2008
America's Top Obstetricians and Gynecologists	2007-Present
US News and World Report – Top Doctors in America	2012-Present
Best Doctors in America	1995-Present
Texas Super Doctors	2004-Present

Best Doctors in Texas	2003-Present
Doctors Across America – Top Doctors	2002-Present
Best Doctors in Austin	2002-Present
Family Building Award- American Fertility Association (National)	2005
International Who’s Who of Executives and Professionals	1999-Present
Prize Paper Award, Society of Reproductive Surgeons	2000
Outstanding Speaker Award, American Association of Clinical Chemistry	2000
Mead Johnson Laboratories/American College of Obstetricians and Gynecologists Focus on Patient Education Award	1991

OTHER:

“Making Miracles: How a Fertility Doctor Fights the Odds as he Tries to help Couples Conceive” Parenting Magazine feature article, September 1999, pgs.126-135.

“Healthy Mind/Healthy Body: Overcoming Infertility” Public Broadcasting System (PBS) Special, Televised Nationally, September, 2006

PATENTS:

Mannose in Vitro Binding Assay and Uses Thereof in Sperm Evaluation Number TB 215259562US.	1994
---	------

COPYRIGHTS:

Cost Analysis for the Infertility Practice	1999
Cost Analysis for the In Vitro Fertilization Practice	1999

GRANTS:

Halt Medical “A prospective, randomized trial of radiofrequency ablation of uterine fibroids”	2016
---	------

Finox Biotech “A phase III investigator- and assessor-blinded randomized, parallel-group multicenter study to compare efficacy and safety of two r-hFSH formulations (AFOLIA pen vs. Gonal-f® RFF pen) in normal ovulatory women 35 to 42 years of age undergoing in vitro fertilization (IVF)”	2013
---	------

Watson Pharmaceuticals “A prospective, randomized controlled trial to assess the effectiveness of luteal phase support using Crinone 8% vaginal gel in clomiphene citrate cycles” Principal Investigator	2011
---	------

EMD Serono, Inc. “A Phase IV multi-national, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of extreme ovarian responses to GONAL-f® treatment in women undergoing assisted reproduction technology (ART)” Principal Investigator	2010
EMD Serono, Inc. “A phase II, multicenter, randomized, assessor blinded, active comparator, dose finding study to evaluate AS900672-enriched versus follitropin alfa (GONAL-f®) in stimulating multiple follicular development in infertile women undergoing assisted reproductive technology (ART)” Principal Investigator	2008
Duramed, Inc. “A Phase 3 Single-Blind Randomized Study to Compare DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Supplementation for In Vitro Fertilization” Principal Investigator	2008
Genzyme, Inc. “A Prospective, Randomized Evaluation of SepraSpray in patients undergoing laparoscopic myomectomy” Principal Investigator	2007
Serono, Inc. “A Prospective multi center randomized trial comparing a new long-acting recombinant FSH product to Gonal F-RFF in patients undergoing IVF” Principal Investigator	2007
Serono, Inc. “A Prospective multi center pilot study for the evaluation of an oocyte freezing/thawing method in patients undergoing ICSI” Principal Investigator	2005
Serono, Inc. “A Prospective, Randomized, Comparative, Single Center Trial to Compare the Safety and Efficacy of Gonal-f RFF versus Gonal-f RFF in combination with Luveris in In-vitro Fertilization” Principal Investigator	2005
ML Laboratories, “A Pivotal, Double-Blind, Comparative, Multicentre Study to Determine the Efficacy and Safety of Adept in the Reduction of Post-Surgical Adhesions After Laparoscopic Surgery”	2003
Chitogenics, Inc., “Safety and Efficacy Study of N,O-carboxymethylchitosan (NOCC)	2003

When Used for Reduction of Postoperative Adhesion Development in Women Undergoing Laparoscopy Principal Investigator	
Serono Laboratories, "Prospective, Randomized Phase 2 Study to assess the safety and efficacy of Anastrozole for the induction of ovulation" Principal Investigator	2003
Confluent Surgical Technologies, "Prospective, Randomized Multi-center two arm double blind study to evaluate the safety and effectiveness of the Spray-Gel Adhesion Barrier System compared to good surgical technique alone in the prevention or reduction of postoperative adhesion formation to the ovaries following laparoscopic gynecologic surgery" Principal Investigator	2002
TAP Pharmaceuticals, "A Phase II, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of J867 in Patients With Endometriosis" Principal Investigator	2001
Serono Laboratories, "A Prospective, Randomized, Comparative Multi-Center Trial to Compare the Safety and Efficacy of Gonal F and Lupron Administered as Single and Separate Injections" Principal Investigator	1999
Connetics Corporation, "A Phase I/II Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Relaxin in Infertile Subjects Undergoing Clomiphene Citrate Therapy" Principal Investigator	1999
Ethicon, Inc., "Assessment of the Safety and Efficacy of Cryo-Ablative Reduction of Menstruation" Principal Investigator	1999
Gliatech, Inc, "A Randomized, Controlled, Cdouble-Masked, Multi-Center Pivotal Study to Evaluate ADCON-P Adhesion Control Barrier Solution in the Reduction of Adhesions Following Peritoneal Cavity Surgery" Principal Investigator	1998
Serono Laboratories, "A Phase III, Multicenter, Double-Blind, Double Dummy, Randomized, Comparative, Multi-Center Trial To Assess the Safety and Efficacy of Recombinant LH with Profasi in Inducing Final Follicular Maturation and Early Luteinization in Infertile Women Undergoing Ovarian Stimulation with Gonal F Prior to IVF and ET", Principal Investigator	1998

Organon Laboratories, "An Open-Label, Randomized Multicenter Study to Assess the Efficacy and Safety of Follistim Solution Formulation Compared to a Freeze-Dried Cake Formulation, for the Induction of Ovulation in Clomiphene Resistant Subjects with Chronic Anovulation" Principal Investigator	1998
TAP Pharmaceuticals, "The Role of an Ultra-Long (3 month) Course Of Depot Lupron Prior to Controlled Ovarian Hyperstimulation (COH) Preparation for in vitro Fertilization/Embryo Transfer in Endometriosis Patients" Principal Investigator	1998
Ethicon Endosurgery, "Evaluation of the Efficacy of Interceed Absorbable Adhesion Barrier in Laparoscopic Treatment of Endometriosis" Principal Investigator	1998
Genzyme Corporation, "Evaluation of the Safety and Application Techniques of Seprigel Bioresorbable Gel in Open and Laparoscopic Gynecologic Pelvic Surgery" Principal Investigator	1996
Serono Laboratories, Inc., "A Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Highly-Purified Human Follicle Stimulating Hormone (Metrodin XP) Administered by the Subcutaneous Route During Pituitary Down-Regulation in IVF/ET" Principal Investigator	1993
Genzyme Corporation, "Evaluation of the Safety and Effectiveness of HAL-C Coating Solution in Surgery" Principal Investigator	1993
National Institute of Health Grant, Cooperative Research Center: Sexually Transmitted Diseases Clinical Core C (main grant under Joel Baseman, Ph.D., Project #SG-2PO1-A122380-403) "The Effect of Acute and Delayed Operative Laparoscopy on the Course of Pelvic Inflammatory Disease" Principal Investigator-Gynecology	1992
TAP Pharmaceuticals "Double Blind Study of Two Doses of Lupron Depot Plus Iron vs. Placebo Plus Iron in the Treatment of Hypermenorrhea Induced Anemia in Patients With Leiomyoma Uteri Principal Investigator	1992

Syntex Pharmaceuticals, "Ninety Days of Treatment With Intranasal Nafarelin Acetate Plus Iron vs. Iron Alone to Improve Anemia Before Surgical Management of Uterine Leiomyomas" Principal Investigator	1991
Humana Corporation Center of Excellence Research Grant "Clinical Assessment of the Fertilization Capability of Human Spermatozoa"	1990

PROFESSIONAL ORGANIZATIONS:

American College of Obstetrics and Gynecology-Fellow	1987-Present
American Society of Reproductive Medicine	1987-Present
Society for Assisted Reproductive Technology	1989-Present
American Association of Gynecologic Laparoscopists	1989-Present
Society of Reproductive Endocrinologists	1991-Present
American Andrology Society	1991-Present
Society for the Study of Reproduction	1992-Present
Pacific Coast Reproductive Society	1993-Present
Society for Male Reproduction & Urology-Charter Member	1996-Present
Society of Reproductive Surgeons	1999-Present

EDITORIAL EXPERIENCE:

Obstetrics & Gynecology	1988-Present
Fertility & Sterility	1989-Present
Journal of Gynecologic Surgery	1990-Present
Journal of the American Medical Association	1992-Present
American Journal of Obstetrics & Gynecology	1992-Present
Journal of the American Association of Gynecologic Laparoscopists	1995-Present
RBM Online	2003-Present
Current Women's Health Reviews, Editorial Board	2004-Present
Journal of Women's Health	2006-Present

PUBLICATIONS:

Papers:

1. Silverberg KM, Olive DL, Schenken RS: Ovarian Cyst Aspiration Prior to Initiating Ovarian Hyperstimulation for *in vitro* fertilization. *J. In Vitro Fert Embryo Transf* 7:153, 1990
2. Falk RM, Silverberg KM, Fetterolf PM, Kirchner FK, Rogers BJ: Establishment of Test-Yolk Buffer Enhanced SPA Limits for Fertile Males. *Fertil Steril* 54:121, 1990

3. Silverberg KM, Boehm FH: Hemophilus Influenza Amnionitis With Intact Membranes: A Case Report. *Am J Perinatol* 7:270, 1990
4. Silverberg KM, Hill GA: Reproductive Surgery vs. Assisted Reproductive Technologies: Selecting the Correct Alternative. *J Gynecol Surg* 7:67, 1991
5. Silverberg KM, Olive DL, Burns WN, Johnson JV, Groff TR, Schenken RS: Follicular Size at the Time of Human Chorionic Gonadotropin Administration Predicts Ovulation Outcome in Human Menopausal Gonadotropin-Stimulated Cycles. *Fertil Steril* 56:296, 1991
6. Silverberg KM, Olive DL, Schenken RS: Progesterone Levels on the Day of Human Chorionic Gonadotropin Administration in Cycles With Gonadotropin-Releasing Hormone Agonist Suppression Are Not Predictive of Pregnancy Outcome. (Letter to the Editor). *Fertil Steril* 56:153, 1991
7. Silverberg KM, Burns WN, Olive DL, Riehl RM, Schenken RS: Serum Progesterone Levels Predict Success of in Vitro Fertilization/Embryo Transfer. *J Clin Endocrinol Metab* 73:797, 1991
8. Silverberg KM, Johnson JV, Olive DL, Burns WN, Schenken RS: A Prospective, Randomized Trial Comparing Two Different Intrauterine Insemination Regimens in Controlled Ovarian Hyperstimulation Cycles. *Fertil Steril* 57:357, 1992
9. Silverberg KM, Klein NA, Burns WN, Schenken RS, Olive DL: Consecutive Versus Alternating Cycles of Controlled Ovarian Hyperstimulation with Human Menopausal Gonadotropin. *Hum Reprod* 7:940, 1992
10. Witz CA, Silverberg KM, Burns WN, Schenken RS, Olive DL: Complications Associated With the Absorption of Hysteroscopic Fluid Media. *Fertil Steril* 60:745, 1993
11. Silverberg KM, Martin M, Olive DL, Burns WN, Schenken RS: Elevated Serum Progesterone Levels on the Day of hCG Administration in IVF Cycles do not Adversely Affect Embryo Quality: Analysis of Subsequent Frozen Embryo Transfers. *Fertil Steril* 61:508, 1994
12. Burns WN, Silverberg KM, Klein NA, Witz CA, Schenken RS: Serum Progesterone Concentrations on the Day After Human Chorionic Gonadotropin Administration and Progesterone/Oocyte Ratios Predict in Vitro Fertilization/Embryo Transfer Outcome. *J Assist Reprod Genet* 11:700, 1994
13. Stovall TG, Muneyyirci-Delale O, Summitt RL, Silverberg K, et al: GnRH Agonist and Iron Versus Placebo and Iron in the Anemic Patient Before Surgery for Leiomyomas: A Randomized Controlled Trial. *Obstet Gynecol* 86:65, 1995.

14. Silverberg KM, Dey TD, Witz CA, Schenken RS: D-Mannose Binding Provides a More Objective Assessment of Male Fertility Than Routine Semen Analysis: Correlation With in Vitro Fertilization. *Fertil Steril*, Submitted.
15. Diamond MP, Bachus K, Bieber E, Bradshaw K, Gallup D, Grunert G, Mok A, Morris R, Perez R, Radwanska E, Silverberg KM, Steinkampf M, Halpern E, Fleming L, Easton C: Comparison of the Reproducibility of Two Standardized Adhesion Scoring Methods. *Fertil Steril*, 1996
16. Silverberg, KM: Ovulation Induction in the Ovulatory Woman. *Sem Reprod Endocrinol*, 14(4):339, 1996.
17. Meldrum, DR, Silverberg KM, Bustillo M, Stokes L: Success Rate With Repeated Cycles of IVF-ET. *Fertil Steril*, 69:1005-9, 1998
18. Diamond MP, Backus K, Silverberg KM, et al: Reduction of de novo Postsurgical Adhesions by Intraoperative Precoating With Sepracoat (HAL-C) Solution: A Prospective, Randomized, Blinded, Placebo-Controlled Multicenter Study. *Fertil Steril* 69:1067-74, 1998.
19. Scott RT, Silverberg KM: Ethics of Guaranteeing Patient Outcomes: A Complex Issue Whose Time Has Not Come. *Fertil Steril* 70:422-24, 1998.
20. Diamond, MP, Silverberg KM, et al: Serum Electrolytes, Chemistries, and Blood Cell Counts after Gynecologic Surgery in Healthy Women. *J Gynecol Tech*. 2001.
21. Daya S, Ledger W, Auray JP, Duru G, Silverberg K, Wikland M, et al. Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK. *Hum Reprod*. 16(12):2563-9, 2001
22. Diamond M, Bieber E, Silverberg K, et al. Pelvic adhesions and Pelvic pain: opinions on cause and effect relationship and when to surgically intervene. *Gynecological Endoscopy* 10:211-16, 2001
23. Silverberg K, Daya S, Auray JP, Duru G, Ledger W, Wikland M, Bouzayen R, O'Brien M, Falk B, Beresniak A: Analysis of the cost effectiveness of recombinant versus urinary follicle stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States. *Fertil Steril*, 77(1) 107-13, 2002
24. Silverberg K. Issues of bioequivalence and cost equivalence. *Fertil Steril* 78 (2):438-40, 2002
25. Silverberg K, Schertz J, Falk B, Beresniak A. Impact of urinary FSH price: a cost effectiveness analysis of recombinant and urinary FSH in assisted reproduction techniques in the USA. *Reprod Biomed Online* Nov/Dec.5 (3) 265-9, 2002.

26. Surrey ES, Silverberg KM, Surrey MW, Schoolcraft WB. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. *Fertil Steril* 78:699-704, 2002
27. Gambone JC, Mittman BS, Windel CA, Silverberg KM, et al. Consensus Statement for the management of chronic pelvic pain and endometriosis: Proceedings of an expert-panel consensus process. *Fertil Steril* 78:961-72, 2002.
28. Daya S, Wikland M, Silverberg K, et al. Quality of life (QOL) differentiation analysis in patients undergoing controlled ovarian stimulation (COS) with two different preparations of recombinant human follicle-stimulating hormone (r-hFSH). *Fertil Steril* 80:137-42, 2003.
29. Garcia J, Kettel LM, Klein N, Silverberg KM, et al. An Aqueous Formulation of Recombinant FSH is More Efficient Than a Freeze-Dried Cake Formulation in Clomiphene-Resistant Women With Chronic Anovulation. *Today's Therapeutic Trends* 22 (3):147-165, 2004.
30. Brown C, Luciano A, Martin D, Silverberg, et al. Adept (Icodextrin4% Solution) reduces adhesions after laparoscopic surgery for adhesiolysis: A double-blind, randomized, controlled study. *Fertil Steril* 12;84-97, 2006.
31. Silverberg KM. Pelvic Adhesions: Prevention through adjunctive therapies. *OBG Management. Suppl*, Sept., 2008.
32. James S, Silverberg KM, Hansard LJ, Burger NZ, Vaughn TC. Rare mullerian anomaly commonly misdiagnosed. *Fertil Steril*, in press, 2009
33. Silverberg KM, Meletiche D, De la Rosa G. An employer's experience with infertility coverage: A case study. *Fertil Steril*, 92:2103-5, 2009.
34. Diamond MP, Fossum GT, Silverberg KM, Miller CE, Holmdahl L, Sepraspray Study Group. Sepraspray, a new option for reduction of postoperative adhesions. *Fertil Steril*, 92:S59, 2009.
35. Miller C, Fossum G, Diamond M, Silverberg K, Holmdahl L. Reduction of postoperative adhesions with Sepraspray: A phase II pilot study. *J Min Invasive Gyn*. 2009.16:S14-15.
36. Szyller A, Silverberg K, Crumb R, Vaughn T, Hansard L, Burger N. Ovarian stromal vascularity evaluated by Doppler correlates with the dose of FSH used during stimulation for IVF-ET. *Fertil Steril*, 92:S47-8, 2009.

37. Boswell K, Silverberg K. Reoccurrence of Ovarian Torsion in a Multiple Pregnancy: Conservative Management via Transabdominal Ultrasound Guided Ovarian Cyst Aspiration. *Fertil Steril*, 94:1910-13, 2010.
38. Fossum G, Silverberg K, Miller CE, Diamond MP, Holmdahl L. Gynecologic Use of Sepraspay for Reduction of Adhesion Development after Laparoscopic Myomectomy: A Pilot Study. *Fertil Steril*, 96:487-91, 2011.
39. Plante M, Smith EB, Cox S, Silverberg K, Reich S. The case of a viable pregnancy post vaginal radical trachelectomy followed by combined chemo-radiation therapy. *Gyn Onc*. 07:022 2011.
40. Silverberg K, Vaughn TC, Hansard LJ, Burger NZ, Minter T. Vaginal (Crinone 8%) gel vs intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. *Fertil Steril*, 97:344-8, 2012
41. Silverberg KM. Focus on Your Fertility: Now and For the Future. *State Bar of Texas Journal, Family Law Section Report*. Volume 2012-2. March, 2012.
42. Stadtmayer L, Silverberg KM, Ginsburg ES. Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. *Fertil Steril*. 99:1543-9, 2013.
43. Davie J, Alper M, Baker V, Beltsos A, Kolb B, Oskowitz S, Silverberg K, Toledo A. Next generation DNA sequencing: improving the accuracy of routine carrier screening. *Fertil Steril*. 101, Issue 2, Supplement.p35, 2014.
44. Shapiro D, Boostanfar R, Silverberg K, Yanushpolsky E. Examining the evidence: Progesterone supplementation during fresh and frozen embryo transfer. *Repro Biomed Online*. 2014;29:S1-14.
45. Silverberg K, Greger V, Neitzel D, Hallam S. Carrier screening with next-generation sequencing detects common, uncommon, and novel mutations. *Obstet Gynecol*. 125:Suppl 1:93S, 2015.
46. Kolb B, Baker V, Beltsos A, Oskowitz S, Silverberg K, Toledo A. Next-generation DNA sequencing: Improving the accuracy of routine carrier screening. *Obstet Gynecol*. 2015.
47. Silverberg K, Davie J, Faulkner N, Greger V, Neitzel D. Carrier screening for spinal muscular atrophy among US in vitro fertilization patients. *Obstet Gynecol*. 125:Suppl 1:93S, 2015.

48. Ginsburg E, Heale J, Jellerette-Nolan T, Silverberg K, et al. Patient experience in a randomized trial of a weekly progesterone vaginal ring vs a daily progesterone gel for luteal support following in vitro fertilization. *Fertil Steril*. 2018. Submitted.

49. Wilman S, Munne S, Kaplan B, Shamma F, Silverberg K, Handyside A, et al. Preimplantation genetic testing for aneuploidy. *N End J Med*. 2018. Submitted

Chapters:

1. Silverberg KM: Combination Therapy for Endometriosis. IN: *Infertility and Reproductive Medicine Clinics of North America*. MP Diamond and AH DeCherney (eds), WB Saunders Company, Philadelphia, 1992, pp. 683-95.

2. Silverberg KM: Suppression of Lactation. IN: *Decision Making in Reproductive Endocrinology and Infertility*. JA Rock and WD Schlaff (eds), Medical Economics Publishers, Oradell, NJ, 1993, pp. 325-8.

3. Silverberg KM: The Evaluation and Management of Non-Galactorrheal Nipple Discharge. IN: *Decision Making in Reproductive Endocrinology and Infertility*. JA Rock and WD Schlaff (eds), Medical Economics Publishers, Oradell, NY, 1993, pp. 320-4.

4. Silverberg KM: Adenomyosis. IN: *Textbook of Gynecology*. J Jerrell and L Copeland (eds), WB Saunders Company, Philadelphia, 1993. pp. 481-504.

5. Silverberg KM, Olive DL: Endometriosis and Adenomyosis. IN: *Textbook of Gynecology*. J Jerrell and L Copeland (eds), 2nd Edition. WB Saunders Company, Philadelphia, 2000. pp.687-722.

6. Silverberg KM: Evaluation of the Couple With Infertility in a Managed Care Environment. IN: *Clinical Obstetrics and Gynecology*. Lippincott Williams & Wilkins, Inc. 2000. Volume 43 (4), pp. 844-53.

7. Silverberg KM, Turner T: Evaluation of Sperm. IN *Textbook of Assisted Reproductive Techniques*. Martin Dunitz Ltd. The Livery House. London. 2001 pp. 61-77.

8. Silverberg KM, Vaughn TC: Unexplained Infertility. IN *Gynecology and Obstetrics*. Maryland Publishing Services. 2003 pp.

9. Silverberg KM, Turner T: Evaluation of Sperm. IN *Textbook of Assisted Reproductive Techniques*. Martin Dunitz Ltd. The Livery House. London. 2nd Edition. 2003, pp.65-78.

10. Silverberg KM, Vaughn TC: Distal Tubal Disease and Hydrosalpinx: Should it be Treated Prior to In Vitro Fertilization? In *The Fallopian Tube in Infertility and IVF Practice*. 2008

11. Silverberg KM, Turner T: Evaluation of Sperm. IN Textbook of Assisted Reproductive Techniques. Martin Dunitz Ltd. The Livery House. London. 4th Edition. 2008.
12. Silverberg KM, Vaughn TC, Burger NZ: Unexplained Infertility. IN Gynecology and Obstetrics, Maryland Publishing Services. Glob. libr. women's med.,(ISSN: 1756-2228) 2008; DOI 10.3843/GLOWM.10324
13. Silverberg KM, Turner T: Evaluation of Sperm. IN Textbook of Assisted Reproductive Techniques. Martin Dunitz Ltd. The Livery House. London. 5th Edition. 2017.

Abstracts:

1. Falk RM, Silverberg KM, Fetterolf PM, Kirchner FK, and Rogers BJ: Establishment of test-yolk buffer enhanced SPA limits for fertile males. Presented at the 44th Annual Meeting of the American Fertility Society, Atlanta, GA, October 10-13, 1988, A# P-12, p.48.
2. Silverberg KM, Groff TR, Riehl RM, Harper MJK, Olive DL, and Schenken RS: Platelet activating factor does not enhance the motility of fresh or cryopreserved human sperm. Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, St. Louis, MO, March 21-24, 1990, A258, p.225.
3. Silverberg KM, Olive DL, and Schenken RS: Does follicular size at the time of hCG administration predict ovulation outcome? Presented at the 46th Annual Meeting of the American Fertility Society, Washington, DC, October 13-18, 1990, A# O-027, p.12.
4. Silverberg KM, Johnson JV, Olive DL, and Schenken RS: A prospective randomized trial to determine the optimal timing of intrauterine insemination following hCG administration after controlled ovarian hyperstimulation. Presented at the 46th Annual Meeting of the American Fertility Society, Washington, DC, October 13-18, 1990, A# P-082, p.100.
5. Silverberg KM, Olive DL, Riehl RM, and Schenken RS: Serum progesterone levels are a critical indicator of premature luteinization and pregnancy outcome in an IVF/ET cycle. Presented at the 46th Annual Meeting of the American Fertility Society, Washington, DC, October 13-18, 1990, A# P-118, p.114.
6. Silverberg KM, Burns WN, Olive DL, and Schenken RS: Serum progesterone levels on the day of hCG administration predict success in cycles of controlled ovarian hyperstimulation. Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, San Antonio, TX, March 20-23, 1991, A# 477, p.337.
7. Silverberg KM, Burns WN, Olive DL, and Schenken RS: The significance of serum progesterone: estradiol ratios on the day of human chorionic gonadotropin administration in

IVF/ET cycles. Presented at the 47 Annual Meeting of the American Fertility Society, Orlando, FL, October 19-24, 1991.

8. Silverberg KM, Klein NA, Burns WN, Schenken RS, and Olive DL: Consecutive versus alternating cycles of controlled ovarian hyperstimulation. Presented at the 47th Annual Meeting of the American Fertility Society, Orlando, FL, October 19-24, 1991.

9. Silverberg KM, Dey T, Olive DL, and Schenken RS: Sperm antibodies induce the acrosome reaction in human spermatozoa in vitro. Presented at the 48th Annual Meeting of the American Fertility Society, New Orleans, LA, October 31-November 5, 1992.

10. Olive DL, Silverberg KM, Klein NA, and Burns WN: A comparison of study design methods for cycle-specific treatments of infertility. Presented at the 48th Annual Meeting of the American Fertility Society, New Orleans, LA, October 31-November 5, 1992.

11. Silverberg KM, Martin M, Olive DL, Burns WN, and Schenken RS: Elevated serum progesterone levels on the day of hCG administration in IVF cycles do not adversely affect embryo quality: Analysis of subsequent frozen embryo transfers. Presented at the 48th Annual Meeting of the American Fertility Society, New Orleans, LA, October 31-November 5, 1992.

12. Silverberg KM, Dey T, and Schenken RS: D-Mannose in vitro binding predicts in vitro fertilization. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada, March 31-April 3, 1993.

13. Silverberg KM, Dey T, Witz CA, and Schenken RS: The modified D-Mannose in vitro binding assay (MBA) predicts fertilization in vitro. Presented at the combined 49th Annual Meeting of the American Fertility Society and the 39th Annual Meeting of the Canadian Fertility and Andrology Society, Montreal, Canada, October 9-14, 1993.

14. Diamond MP, Bachus K, Bieber E, Bradshaw K, Gallup D, Grunert G, Mok A, Morris R, Perez R, Radwanska E, Silverberg KM, Steinkampf M, Halpern E, Fleming L, and Easton C: Comparison of the reproducibility of two standardized adhesion scoring methods. Presented at the combined 49th Annual Meeting of the American Fertility Society and the 39th Annual Meeting of the Canadian Fertility and Andrology Society, Montreal, Canada, October 9-14, 1993.

15. Silverberg KM, Dey T: The mannose-binding assay is more reproducible than sperm concentration, motility, or morphology. Presented at the Annual Meeting of the American Society of Andrology, Raleigh, North Carolina, April 2-5, 1995.

16. Silverberg KM, Awadalla SG, Grainger D, Jacobson A, Katayama P, Kenigsberg D, et al: A phase 3, open-label, multicenter study to evaluate the safety and efficacy of Metrodin XP for in vitro fertilization. Presented at the 9th World Congress on In Vitro Fertilization and Assisted Reproduction, Vienna, Austria, April 3-7, 1995.

17. Silverberg KM, Dey T: The avidin biotin complex D-mannose binding assay predicts fertilization in vitro. Presented at the Annual Meeting of the Pacific Coast Fertility Society, Coronado, California, April 26-30, 1995.
18. Diamond MP, Ackerman G, Silverberg KM, et al: Adhesions: Effect on pregnancy outcome. Presented at the World Congress of Gynecologic Endoscopy, Orlando, Florida, November 7-12, 1995.
19. Diamond MP, Silverberg KM, et al: Precoating with Sepracat (HAL-C) Reduces Postoperative De Novo Adhesion Formation In A Multicenter Randomized, Placebo-Controlled Gynecologic Clinical Trial. Presented at the 43rd Annual Meeting of the Society for Gynecologic Investigation, Philadelphia, PA, March 20-23, 1996.
20. Kelly E, Silverberg KM, et al: Recombinant FSH Therapy Alone (Gonal-F) Versus Combination Therapy (Gonal-F + LHadi) in Patients Down Regulated With Low Dose Luteal GnRH Agonist Protocol: Preliminary Results". Presented at the 11th World Congress on In Vitro Fertilization, Sydney, Australia, May 9-14, 1999.
21. Silverberg KM, Ormand RA, Hansard LJ, Turner T, Slapak J, Williamson B, and Vaughn TC: Ultra-low Dose Lupron Flare Offers Improved Outcome for Poor Resonders. Presented at the 55th Annual meeting of the American Society for Reproductive Medicine. Toronto, Canada, September 25, 1999.
22. Silverberg KM, Ormand RA, Hansard LJ, and Vaughn TC: Clomiphene Citrate Improves Sperm Quality and Fertility in Hypogonadal, Oligospermic Males. Presented at the 55th Annual meeting of the American Society for Reproductive Medicine. Toronto, Canada, September 27, 1999.
23. Silverberg KM, Montgomery Rice V, Ormand R, Karst A, Vaughn T, Hansard L: Recombinant Human Follicle Stimulating Hormone (rFSH, Gonal-F) and Leuprolide Acetate (LA, Lupron) Administered in Single or Separate Injections in Women Undergoing in vitro Fertilization (IVF): Preliminary Results. Presented at the Annual Meeting of the European Society of Human Reproduction and Endocrinology. Bologna, Italy, June 25, 2000.
24. Silverberg KM, Ormand RA, Hansard LJ, and Vaughn TC: The Intercycle Variability in Patients Treated With Repeated Cycles of Gonadotropins is Due to Intrinsic Factors and is Not Eliminated by Recombinant Gonadotropins. Presented at the 56th Annual meeting of the American Society for Reproductive Medicine, San Diego, California. October, 2000
25. Diamond MP, Tedford CE, Silverberg KM, et al. Assessment of Pelvic Adhesions: Statistical Validation, Reliability and Interobserver Correlation Using a Modification of the More Comprehensive Adhesion Scoring Method (MCASM). Presented at the 56th Annual meeting of the American Society for Reproductive Medicine, San Diego, California. October, 2000.

26. Montgomery-Rice V, Silverberg K, Karst A, Ormand R, et al. Patient Tolerance to Recombinant Human Follicle Stimulating Hormone (r-hFSH, Gonal-F®) and Leuprolide Acetate (LA, Lupron®) Administered in Single or Separate Injections in Women Undergoing IVF; Preliminary Results. Presented at the 56th Annual meeting of the American Society for Reproductive Medicine, San Diego, California. October, 2000.
27. Silverberg KM, Ormand RA, Hansard LJ, Vaughn TC. Weight Correlates with Gonadotropin Requirements and Patient Response. Presented at the 56th Annual meeting of the American Society for Reproductive Medicine, San Diego, California. October, 2000.
28. Silverberg KM, Schertz J, Falk B, Beresniak A. Impact of Price Variability on Cost-Effectiveness Modeling of rFSH Vs. uFSH in ART in the United States. Presented at the 2nd Annual Controversies in OB/GYN and Infertility Meeting, Paris, France, September, 2001.
29. Silverberg KM, Ormand R, Hansard LJ, Vaughn TC. Poor Response to Ovarian Hyperstimulation Predicts Spontaneous Ovulation. Presented at the 57th Annual meeting of the American Society for Reproductive Medicine. Orlando, FL. October, 2001.
30. Surrey ES, Silverberg KM, Surrey MW, Schoolcraft WB. The effect of prolonged GnRH agonist therapy on in vitro fertilization-embryo transfer cycle outcome in endometriosis patients: a multicenter randomized trial. Presented at the 57th Annual meeting of the American Society for Reproductive Medicine. Orlando, FL. October, 2001.
31. Silverberg KM, Ormand R, Hansard LJ, Vaughn TC. Recombinant FSH Provides More Efficient, Cost-Effective Stimulation for Ovulation Induction/Intrauterine Insemination (OI/IUI) Cycles Than Highly Purified Urinary FSH. Presented at the 57th Annual meeting of the American Society for Reproductive Medicine. Orlando, FL. October, 2001.
32. Daya S, Wikland M, Silverberg K, Blatz S, Duru G, Beresniak A. Quality of life (QOL) differentiation analysis in patients undergoing controlled ovarian stimulation (COS) with two different preparations of recombinant human follicle-stimulating hormone (r-hFSH). Presented at the 59th Annual Meeting of the American Society for Reproductive Medicine, San Antonio, Texas, USA, October 11-15, 2003
33. Silverberg KM, Minter T, Hansard LJ, Vaughn TC. High order multiples and gonadotropin/IUI cycles: how can we reduce the risks? Presented at the 60th Annual Meeting of the American Society for Reproductive Medicine, Philadelphia, PA, October 20, 2004.
34. Silverberg KM, Werland H, Turner T, Fields R, Schuster C, Hansard LJ, Vaughn TC. Suboptimal embryo morphology on day 3 does not predict poor pregnancy potential. Presented at the 61st Annual Meeting of the American Society for Reproductive Medicine, Montreal, Canada, October 18, 2005.

35. Silverberg KM, Werland H, Turner T, Fields R, Schuster C, Hansard LJ, Vaughn TC. Choosing the optimal incubator environment: triple gas vs. 5% CO₂ in air, a prospective, randomized trial. Presented at the 61st Annual Meeting of the American Society for Reproductive Medicine, Montreal, Canada, October 16, 2005.
36. Silverberg KM, Werland H, Turner T, Fields R, Crowl C, Hansard LJ, Vaughn TC. Determining the Predictive Value of Day 3 Embryonic Morphology and Cell Stage on Ultimate Embryo Quality. Presented at the 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 22, 2006.
37. Silverberg KM, Minter TM, Vaughn TC. Recombinant FSH Alone vs. Combination FSH/LH Stimulation: A Prospective Trial. Presented at the 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 22, 2006.
38. Silverberg KM, Minter TM, Basuray R. Gonal F-RFF vs. Gonal F Multi-Dose for IVF Stimulation: A Prospective, Sequential Trial. Presented at the 62nd Annual Meeting of the American Society for Reproductive Medicine, New Orleans, LA, October 22, 2006.
39. Luna M, Martinuzzi K, Silverberg K, Treiser S, Kolb B, Copperman AB. Elective Oocyte Cryopreservation for Fertility Preservation: A National Perspective. Presented at the 2007 Meeting of the American College of Obstetricians and Gynecologists, San Diego, CA, May 8, 2007.
40. Fields R, Turner T, Werland H, Pogson K, Vaughn T, Silverberg K. Can We Predict Blastocyst Viability Based on Day 3 Embryo Development? Presented at the 63rd Annual Meeting of the American Society for Reproductive Medicine, Washington, DC. October 15, 2007.
41. Turner T, Fields R, Werland H, Hansard L, Vaughn T, Silverberg K. Determining the Predictive Value of Day 3 Embryonic Morphology and Cell Stage on Ultimate Embryo Quality. Presented at the 63rd Annual Meeting of the American Society for Reproductive Medicine, Washington, DC. October 16, 2007.
42. Szyller A, Silverberg K, Crumb R, Vaughn T, Burger N, Hansard L. Ovarian Stromal Vascularity Evaluated By Doppler Correlates With The Dose Of FSH Used During in vitro fertilization(IVF) Stimulation. Presented at the 65th Annual Meeting of the American Society for Reproductive Medicine, Atlanta, GA. October, 2009.
43. Szyller A, Silverberg K, Crumb R, Vaughn C, Hansard L, Burger N. A Prospective, Observational, Comparative Single Center Trial to Predict In Vitro Fertilization and Embryo Transfer Outcome by Ovarian Ultrasound Doppler Measurements. Annual Meeting of the American Institute of Ultrasound In Medicine, San Diego, CA, March, 2010.

44. Silverberg K, Vaughn T, Hansard L, Burger N, Minter T. Progesterone Vaginal Gel vs. Intramuscular Progesterone in Oil for Luteal Support in IVF: A Large, Prospective Trial. Presented at the 66th Annual Meeting of the American Society for Reproductive Medicine, Denver, CO. October, 2010
45. Vaughn T, Silverberg K, Hansard L, Burger N. Selection of Young Patients Using Strict Criteria Allows an Excellent Chance of Pregnancy When Transferring a Single Embryo While Avoiding a High Risk of Multiple Gestation. Presented at the 66th Annual Meeting of the American Society for Reproductive Medicine, Denver, CO. October, 2010
46. Silverberg K, Howard B. Demonstration of efficacy of a novel progesterone vaginal ring compared to a daily progesterone gel for luteal phase supplementation after in vitro fertilization (IVF). Presented at the Annual Meeting of the American College of Obstetricians and Gynecologists, Washington DC. May, 2011
47. Silverberg K, Reape K, Howard B. Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phase supplementation by body mass index (BMI). Presented at the 67th Annual Meeting of the American Society for Reproductive Medicine, Orlando, FL. October, 2011.
48. Silverberg KM, Minter TL, Silverberg KM, Vaughn TC, Hansard LJ, Burger NZ. Both AMH and day 3 FSH levels predict IVF stimulation outcome regardless of patient age; Day 3 estradiol levels are not predictive. Presented at the 68th Annual Meeting of the American Society for Reproductive Medicine, San Diego, CA. October, 2012.
49. Silverberg KM, Howard B. Satisfaction with progesterone vaginal ring (PGN VR): Survey of women participating in a randomized trial of weekly PGN VR vs. 8% PGN gel as luteal support after in vitro fertilization (IVF). Presented at the 68th Annual Meeting of the American Society for Reproductive Medicine, San Diego, CA. October, 2012.
50. Fields R, Werland H, Pogson K, Turner T, Silverberg KM. Laser collapsing of blastocysts prior to vitrification leads to better embryonic survival and improved overall IVF cycle outcome. Presented at the 69th Annual Meeting of the American Society for Reproductive Medicine, Boston, MA, October, 2013
51. Hall A, Zain R, Silverberg KM, The institution of an active social media campaign increases new and returning web traffic and drives patient conversion. Presented at the 69th Annual Meeting of the American Society for Reproductive Medicine, Boston, MA, October, 2013
52. Silverberg K, Davie J, Faulkner N, Greger V, Neitzel D. Carrier screening for spinal muscular atrophy among US IVF patients. Presented at the 2015 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists, San Francisco, CA, May, 2015.

53. Silverberg K, Neitzel D, Greger V, Hallam S. Carrier screening with next-generation sequencing detects common, uncommon, and novel mutations. Presented at the 2015 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists, San Francisco, CA, May, 2015.
54. Picou A, Hellmers A, Werland H, Turner T, Silverberg K. A comparison of pregnancy rates of frozen embryo transfers of vitrified blastocysts to vitrified euploid blastocysts. Presented at the 71st Annual Meeting of the American Society for Reproductive Medicine, Baltimore, MD, October, 2015.
55. Picou A, VerMilyea M, Werland H, Sieren K, Silverberg K. Blastocyst morphology is a poor indicator of euploid status. Presented at the 72nd Annual Meeting of the American Society for Reproductive Medicine, Salt Lake City, UT, October, 2016.
56. VerMilyea M, Werland H, Sieren K, Silverberg K. Day 5, 6, and 7 blastocyst ploidy status stratified by patient age. Presented at the 72nd Annual Meeting of the American Society for Reproductive Medicine, Salt Lake City, UT, October, 2016.
57. Munne S, Kaplan B, Silverberg K, et al. Global multicenter randomized controlled trial comparing single embryo transfer with embryo selected by preimplantation genetic screening using next-generation sequencing versus morphologic assessment. Presented at the 73rd Annual Meeting of the American Society for Reproductive Medicine, San Antonio, TX, October, 2017.
58. Gavrizi S, Silverberg B, Silverberg K. Examining the luteal placental shift in pregnancy following frozen embryo transfer. Presented at the 73rd Annual Meeting of the American Society for Reproductive Medicine, San Antonio, TX, October, 2017.
59. Rios C, Baker W, Aguirre M, Silverberg K, VerMilyea M. An initial review of next generation screening: A new service provider for comprehensive chromosomal screening (CCS) by next generation sequencing (NGS). Presented at the 73rd Annual Meeting of the American Society for Reproductive Medicine, San Antonio, TX, October, 2017.
60. Propst A, Hansard L, Silverberg K, Hegtvedt M, Burger N, Vaughn T. Endometrial receptivity and pregnancy rates are higher after 7 days of progesterone in medicated FET cycles. Presented at the 73rd Annual Meeting of the American Society for Reproductive Medicine, San Antonio, TX, October, 2017.
61. Werland H, VerMilyea M, Silverberg K. Culturing embryos to Day 7. A viable option for IVF patients? Presented at the 73rd Annual Meeting of the American Society for Reproductive Medicine, San Antonio, TX, October, 2017.
62. Miller A, Rios C, Silverberg K, VerMilyea M. Euploid rate of embryos derived from aspirated and ejaculated sperm. Presented at the Annual Meeting of the European Society for Human Reproduction and Embryology. Barcelona, Spain, July, 2018.

63. Rios CM, Whitney JB, VerMilyea M, Jones A, Picou A, Balloch K, Nugent N, Silverberg K, Anderson RE, Schiewe MC. Increased scrutiny of NGS profiles/ranking does not improve eSET implantation of euploid blastocysts: A randomized comparative trial. Presented at the Annual Meeting of the European Society for Human Reproduction and Embryology. Barcelona, Spain, July, 2018

VIDEOTAPES

Silverberg KM, Burns WN, Bonds SH, and Schenken RS: Laparoscopic gonadectomy for androgen insensitivity. Presented at the 47th Annual Meeting of the American Fertility Society, Orlando, FL, October 19-24, 1991.

Olive DL, Silverberg KM, et al: Infertility. Time Life Medical Video Productions. New York, New York, 1996.

GRAND ROUNDS, INVITED LECTURES, POSTGRADUATE COURSES (ABBREVIATED)

1. "Reproductive Surgery vs. Assisted Reproductive Technology: Selecting the Correct Alternative", Vanderbilt University Medical Center, Nashville, TN, May, 1989.
2. "Endocrinologic Aspects of the Maternal Adaptation to Pregnancy", The University of Texas Health Science Center at San Antonio, September, 1989.
3. "IVF, GIFT, and ZIFT", Infertility Public Forum, Wyndham Hotel, San Antonio, TX, April, 1990.
4. "The Use of Serum Progesterone Levels on the Day of hCG Administration as a Prognostic Indicator of Outcome in IVF/ET Cycles", Texas IVF and GIFT Programs Conference, Austin, TX, May, 1990.
5. "Endometriosis: The Evolving Role of GnRH Agonists in Medical and Surgical Management", Infertility Public Forum, Wyndham Hotel, San Antonio, TX, April, 1991.
6. "Physiology of Ovulation", Serono Symposia USA, Plaza Hotel, San Antonio, TX, November, 1991.
7. "Female Infertility", Serono Symposia USA, Plaza Hotel, San Antonio, TX, November, 1991.
8. "Cycle Monitoring and Administration of Gonadotropins", Serono Symposia USA, Plaza Hotel, San Antonio, TX, November, 1991.

9. "Ovulation Induction Using Human Menopausal Gonadotropins: The Art and the Science", Grand Rounds, Yale University School of Medicine, New Haven, CT, January, 1992.
10. "In Vitro Fertilization: Where We Are and Where We Are Going", Grand Rounds, The University of Texas Health Science Center, San Antonio, TX, February, 1992.
11. "Contemporary Diagnosis and Treatment of Endometriosis", Grand Rounds, Brooke Army Medical Center, San Antonio, TX, March, 1992.
12. "Elevated Serum Progesterone Levels on the Day of hCG Administration in IVF Cycles Do Not Adversely Affect Embryo Quality", Texas IVF Program Conference, Austin, TX, April, 1992.
13. "New Directions in Urology: Male Infertility", Urology Center of Excellence, La Mansion del Rio Hotel, San Antonio, TX, June, 1992.
14. "Female Infertility", Grand Rounds, Bethesda Hospital, Cincinnati, OH, July, 1992.
15. "Basic and Intermediate Operative Laparoscopy", Course Co-Director, Conchita Maternity Hospital, Monterrey, Mexico, August, 1992.
16. "Andrology Testing: What Do The Tests and Numbers Mean", Serono Symposia USA, The Plaza Hotel, San Antonio, TX, September, 1992.
17. "Advanced Operative Laparoscopy", Course Co-Director, University of Nuevo Leon Medical School, Monterrey, Mexico, October, 1992.
18. "Ovulatory Dysfunction and Ovulation Induction", Grand Rounds, Vanderbilt University Medical Center, Nashville, TN, October, 1992.
19. "The Evaluation and Management of Non-Galactorrheal Nipple Discharge", The University of Texas Health Science Center Breast Disease 1993 Course, Houston, TX, January, 1993.
20. "Current Status of Gamete Donation in Texas", Resolve of North Texas, City Place, Dallas, TX, April 3, 1993.
21. "Gynecology Update: Application of New Surgical Techniques and Medical Management", Co-Moderator, Satellite Teleconference, Richmond, VA, May, 1993.
22. "Current Status of Gamete Donation in Texas", Grand Rounds, The University of Texas Health Science Center, San Antonio, TX, June, 1993.
23. "Medical Management of Uterine Fibroids", Corpus Christi OB/GYN Society, Corpus Christi, TX, June, 1993.

24. "Ovarian Hyperstimulation Regimens for Poor Responders", Society for Assisted Reproductive Technology (SART) Postgraduate Course, Montreal (Quebec), Canada, October, 1993.
25. "Advanced Technology for Infertility", Doctors Regional Medical Center, Corpus Christi, TX, October, 1993.
26. "Contemporary Diagnosis and Treatment of Endometriosis", Grand Rounds, Knapp Regional Medical Center, Weslaco, TX, October, 1993.
27. "Contemporary Medical and Surgical Management of Uterine Fibroids", Grand Rounds, Brackenridge Hospital, Austin, TX, November, 1993.
28. "Current Status of Gamete/Embryo Donation in Texas", The 65th Annual Meeting of the Texas Association of Obstetricians and Gynecologists, San Antonio, TX, March, 1994.
29. "Conservative Management of Ectopic Pregnancy", Co-Director, Postgraduate Course, The American College of Obstetricians and Gynecologists 42nd Annual Meeting, Orlando, FL, May, 1994.
30. "The Application of Ultrasound Technology to the Diagnosis and Treatment of Infertility", Southwest Ultrasound Society, San Antonio, TX, May, 1994.
31. "Contemporary Management of Uterine Fibroids", Grand Rounds, The University of Texas Health Science Center at Houston, June, 1994.
32. "Contemporary Management of Uterine Fibroids", Grand Rounds, The University of Texas Medical Branch, Galveston, TX, June, 1994.
33. "Infertility Evaluation for the Gynecologist: A Managed Care Perspective", Vanderbilt Lonnie Burnett Society Meeting, Destin, FL, June, 1994.
34. "Contemporary Management of Uterine Fibroids", Grand Rounds, Baylor University Medical Center, Dallas, TX, August, 1994.
35. "Contemporary Evaluation of Male Factor Infertility", Resolve of North Texas, City Place, Dallas, TX, September, 1994.
36. "Medical and Surgical Management of Endometriosis", Controversies in Gynecology: A Managed Care Perspective. Scottsdale, AZ, October, 1994.
37. "Health Care Reform 1995: An OB/GYN Perspective", James Datillo Lectureship, Mercy Hospital. Pittsburgh, PA, February, 1995.

38. "The Role of Outcomes Research in the OB/GYN Practice", Gynecology in the '90s. The New Era of Managed Care. Hawaii, Hawaii, March, 1995.
39. "Cost Effective Management of Infertility", Gynecology in the '90s. The New Era of Managed Care. Hawaii, Hawaii, March, 1995.
40. "Hormone Replacement Therapy and Breast Cancer: Is the Risk Worth Taking?", Gynecology in the '90s. The New Era of Managed Care. Maui, Hawaii, March, 1995.
41. "How Do You Stimulate the Poor Responder?", Postgraduate course, 43rd Annual Meeting of the Pacific Coast Fertility Society, Coronado, California, April 26-30, 1995.
42. "Male Factor Infertility and Sperm Function Testing", Medical City Hospital, Dallas, Texas, July 18, 1995.
43. "A Cost Effective Approach to the Diagnosis of Infertility", Grand Rounds, The University of Texas-Southwestern Medical School, Dallas, Texas, September 6, 1995.
44. "Extending GnRH Analog Therapy: Add-Back Regimens", Update 1995: Current Issues and New Techniques in Gynecology, San Antonio, Texas, October 20-21, 1995.
45. "Male Factor Infertility and Sperm Function Testing", Grand Rounds, The University of California at San Diego, January 10, 1996.
46. "Sperm Function Testing and Intrauterine Insemination", 44th Annual Meeting of the Pacific Coast Fertility Society, Palm Springs, California, April 17-21, 1996.
47. "Cost Effective Diagnosis and Treatment of Infertility", Update 1996: Current Issues and New Techniques in Gynecology, Dallas, Texas, April 26, 1996.
48. "Surgical Management of Endometriosis", Update 1996: Current Issues and New Techniques in Gynecology, Dallas, Texas, April 26, 1996.
49. Testimony before the Federal Food and Drug Administration on the use of gonadotropins in the United States. Bethesda, Maryland, June 14, 1996.
50. "Reevaluating Stimulation Protocols for in vitro fertilization", Irvine, Sacramento, California, December 4, 1996.
51. "Reevaluating Stimulation Protocols for Assisted Reproductive Technologies", Grand Rounds, The University of Cincinnati School of Medicine, Cincinnati, Ohio, January 30, 1997.

52. Testimony before the Federal Food and Drug Administration on SepraCoat liquid adhesion preventative. Bethesda, Maryland, February 10, and May 5, 1997.
53. "Contemporary Medical Management of Endometriosis", Grand Rounds, The University of Colorado School of Medicine, Denver, Colorado, February 11, 1997.
54. "Targeted Infertility Evaluation", Update 1997: Contemporary Issues in Gynecology. New Techniques and Advances. Houston, Texas, February 14, 1997.
55. "The Contemporary Prevention of Pelvic Adhesions", Keynote Speaker-Research Day, Laval University School of Medicine, Quebec City, Canada, April 17, 1997.
56. "Reevaluating Stimulation Protocols for in vitro fertilization", University of South Florida School of Medicine, Tampa, Florida, May 14, 1997.
57. "Reevaluating Stimulation Protocols for in vitro fertilization", Pacific Fertility Center, Honolulu, Hawaii, July 8, 1997.
58. "The Contemporary Prevention of Pelvic Adhesions", Grand Rounds, Cedars Sinai Medical Center, Los Angeles, California, August 20, 1997.
59. "Tubal Surgery vs. Assisted Reproductive Technology: Selecting the Correct Alternative", Postgraduate course, The American Association of Gynecologic Laparoscopists Annual Meeting, Seattle, WA, September 24, 1997.
60. "Sperm Function Testing: In Search of the Optimum Sperm", Postgraduate course, The American Society for Reproductive Medicine Annual Meeting, Cincinnati, OH, October 18-19, 1997.
61. "Improving Infertility Insurance Coverage." Infertility Management Seminar, New Orleans, LA, December 11-12, 1997.
62. "Evolution of the New Gonadotropins", Pacific Northwest Reproductive Endocrinology Society, Seattle, WA, January 13, 1998.
63. "Cost Effective Diagnosis of Infertility", Grand Rounds, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, January 14, 1998.
64. "Development of the Recombinant Gonadotropins", Postgraduate course, Pacific Coast Fertility Society, Indian Wells, CA, April 23, 1998.
65. "Evolution of the New Gonadotropins", 13th Congress of the European Association of Gynaecologists and Obstetricians, Jerusalem, Israel, May 12, 1998.

66. "Optimizing Stimulation Regimens for ART", Boston Infertility Society, Boston, MA, May 20, 1998.
67. "Prevention of Postoperative Pelvic Adhesions", Postgraduate Course, American Society of Reproductive Medicine, Boston, MA, May 21, 1998.
68. "Tubal Surgery vs. Assisted Reproductive Technology", Postgraduate Course, American Society of Reproductive Medicine, Boston, MA, May 22, 1998.
69. "Cost Effective Diagnosis of Infertility", Infertility Management: Improving Outcomes & Reducing Costs, Boston, MA, June 19, 1998.
70. "Evolution of the New Gonadotropins", 20 Years From Start to ART: Current Concepts for Nurses in Reproductive Medicine, Orlando, FL, August 27, 1998.
71. "Avoiding Complications of Operative Hysteroscopy": Grand Rounds, Sparrow Hospital, Lansing, MI, October 27, 1998.
72. "Cost Effective Diagnosis and Treatment of Infertility", Grand Rounds, Thomas Jefferson School of Medicine, Department of OB/GYN, Philadelphia, PA, December 17, 1998.
73. "Cost Effective Diagnosis of Infertility", Post-Graduate Course, American Society of Reproductive Medicine, Houston, Texas, March 20, 1999.
74. "The Clinical Diagnosis of Endometriosis", Making a Difference: New Treatment Strategies for Difficult Gynecologic Disorders, Las Vegas, Nevada, April 9, 1999.
75. "Recombinant Technology: Clinical Update and Case Study Review", Moderator and Presenter. Santa Barbara, California, June 4-6, 1999.
76. "The Use of GnRH Analogs for Clinically Proven Endometriosis", Making a Difference: New Treatment Strategies for Difficult Gynecologic Disorders, San Francisco, California, July 30, 1999.
77. "Giving the Stork a Hand: The Truth About Fertility Drugs", 47th Annual Postgraduate Pharmacy Seminar. University of Texas School of Pharmacy. September 12, 1999.
78. "Contemporary Management of the Endometrioma", Making a Difference: New Treatment Strategies for Difficult Gynecologic Disorders, Phoenix, Arizona, September 17, 1999.
79. "Contemporary Management of Chronic Pelvic Pain", Harvard Pilgrim Healthcare System, Boston, Massachusetts, October 19, 1999.

80. "Cost Analysis and Management Solutions for the OB/GYN Practitioner", Optimistic Future Program, La Jolla, California, April 7-9, 2000.
81. "Cost Analysis and Management Solutions for the OB/GYN Practitioner", Optimistic Future Program, Washington DC, June 3, 2000.
82. "Cost Effective Diagnosis of Infertility". Grand Rounds, The University of New Mexico School of Medicine. Albuquerque, New Mexico, September 8, 2000.
83. "Managed Care and Infertility Coverage", The Metropolitan Area Infertility Nurses – Infertility: The New Millenium Overview. New York, NY, September 23, 2000.
84. "Activity Based Costing for the Infertility Practice", Practice Management Postgraduate Course, 56th Annual Meeting of the American Society for Reproductive Medicine. San Diego, CA, October 21, 2000.
85. "Optimizing Infertility Treatment Strategies for 2000 and Beyond", Symposium Chairman and Presenter, 56th Annual Meeting of the American Society for Reproductive Medicine. San Diego, CA, October 23, 2000.
86. "Improving the Cost Effectiveness of Infertility Therapy", Symposium Chairman and Presenter, 56th Annual Meeting of the American Society for Reproductive Medicine. San Diego, CA, October 25, 2000.
87. "Determining Your Costs in an OB/GYN Practice Environment", Grand Rounds, Washington University School of Medicine, St. Louis, MO. November 29, 2000.
88. "Determining Your Costs in an OB/GYN Practice Environment", Grand Rounds, Cedars Sinai Medical Center, Los Angeles, CA. January 10, 2001.
89. "Determining Your Costs in an OB/GYN Practice Environment", Changing Perspectives, A New Outlook on Gynecologic Disorders. Atlanta, GA. February 9, 2001.
90. "Reproductive Surgery vs. ART: Selecting the Correct Alternative". PostGraduate Course, Annual meeting of the Pacific Coast Reproductive Society, Palm Springs, CA April 26, 2001
91. "Contemporary Treatment of Endometriosis", Phoenix OB/GYN Society Annual Meeting, Phoenix, AZ. May 22, 2001.
92. "Determining Your Costs in an OB/GYN Practice Environment", Annual Meeting of the Lonnie Burnett Society, Vanderbilt University Medical Center, Nashville, TN. June 8, 2001.
93. Chairman, Symposium on Latest Advances in the Treatment of Infertility. Turnberry Island Resort, Ft. Lauderdale, FL. June 22-24, 2001.

94. "Can You Afford That Managed Care Contract?", Changing Perspectives: A New Outlook on Gynecologic Disorders. Detroit, MI, August 17, 2001.
95. "Alternative Medical Therapies for Endometriosis", Phoenix OB/GYN Society, Phoenix, AZ, February 21, 2002.
96. "Optimizing Surgical Outcomes for Endometriosis Patients", Grand Rounds, St. Joseph's Hospital, Phoenix, AZ, February 22, 2002.
97. "Determining Your Costs in an OB/GYN Practice Environment", Changing Perspectives: A new Outlook on Gynecologic Disorders, Los Angeles, CA. March 1, 2002.
98. "Determining Your Costs in an OB/GYN Practice Environment", University of Florida Annual Post-Graduate Course, Pensacola, FL June 29, 2002.
99. "Cost Effective Diagnosis of Infertility", Changing Perspectives: A new Outlook on Gynecologic Disorders, Atlanta, GA September 6, 2002.
100. "Cost Effective Diagnosis of Infertility", Milwaukee Gynecological Society Annual Meeting, Milwaukee, WI, October 1, 2002.
101. "Determining Your Costs in an OB/GYN Practice Environment", Women's Hospital Department of OB/GYN, Baton Rouge, LA, January 28, 2003.
102. "Cost Effective Diagnosis of Infertility", Changing Perspectives: A new Outlook on Gynecologic Disorders, Miami, FL April 4, 2003.
103. "Determining Your Costs in an OB/GYN Practice Environment", Annual Meeting of the Independent Practice Association of America. Las Vegas, NV April 8, 2003.
104. "Stimulating the Poor Responder", San Diego Reproductive Endocrinology Society Meeting. April 8, 2003.
105. "Stimulating the Poor Responder", Miami Reproductive Endocrinology Society Meeting, May 6, 2003.
105. "Stimulating the Poor Responder", Atlanta Reproductive Endocrinology Society Meeting, June 3, 2003.
106. "The Use of Recombinant FSH in Ovulation Induction", Charlotte Reproductive Endocrine Society Meeting, October 20, 2003.

107. “Stimulating the Poor Responder”, Greenville OB/GYN Society Meeting, Greenville, SC, October 21, 2003.
108. “Update on In Vitro Fertilization and ICSI”, OB/GYN Society of Nuevo Leon, Monterrey, Mexico, May 21, 2004.
109. “Cost Effective Diagnosis of Infertility”, Annual Meeting of the Georgia/South Carolina OB/GYN Society, Hilton Head, SC, September 10, 2004
110. “Contemporary Prevention of Pelvic Adhesions”, Annual Meeting of the Georgia/South Carolina OB/GYN Society, Hilton Head, SC, September 11, 2004.
111. “OB/GYNs and REs: Building Bridges For Better Patient Care”, Serono Symposium. American Society for Reproductive Medicine, Philadelphia, PA, October 19, 2004.
112. “Contemporary Medical and Surgical Management of Endometriosis”, Ft. Worth OB/GYN Society Meeting & Grand Rounds – Department of Obstetrics & Gynecology, John Peter Smity Hospital, Ft. Worth, Texas, January 24, 2005.
113. “What’s New In Stimulation Protocols: Stimulating the Poor Reponder”, Midwest Reproductive Symposium, Chicago, IL, June 3, 2005.
114. “OB/GYNs and REs: Building Bridges For Better Patient Care”, Los Angeles OB/GYN Society Meeting, Los Angeles, CA, December 1, 2005.
115. “Infertility in a Manged Care Environment”, Symposium Director, Academy of Managed Care Pharmacies Annual Meeting, Seattle, WA, April 5, 2006.
116. “Contemporary Medical and Surgical Management of Endometriosis”. Washington, DC, November 3, 2006
117. “Pathophysiology and Prevention of Pelvic Adhesions”, Grand Rounds, Scott & White Medical Center, Temple, TX, January 18, 2007.
118. “Contemporary Medical and Surgical Management of Endometriosis”. Salt Lake City, UT May 18, 2007
119. “Contemporary Medical and Surgical Management of Endometriosis”. St. Louis, MO, June 1, 2007
120. “Pathophysiology and Prevention of Pelvic Adhesions”, St. Louis OB/GYN Society Meeting, St. Louis, MO, July 19, 2007
121. “Pathophysiology and Prevention of Pelvic Adhesions”, Boston, MA, September 7, 2007

122. “Identifying Bio-Markers of Optimal Embryo Quality”, Phoenix Reproductive Endocrine Society, Phoenix, AZ September 27, 2007
123. “Pathophysiology and Prevention of Pelvic Adhesions”, Columbus OB/GYN Society, Columbus, OH, October 17, 2007.
124. “Pathophysiology and Prevention of Pelvic Adhesions”, Dallas, TX, November 2, 2007.
125. “Current Status of Oocyte Cryopreservation”, New York OB/GYN Society, New York, NY, November 13, 2007
126. “Current Status of In Vitro Fertilization in the United States”, OB/GYN Grand Rounds, Mount Sinai Medical Center, New York, NY, November 14, 2007.
127. “Reducing Infertility Patient Drop Out”, Los Angeles Reproductive Endocrine Society, Santa Monica, CA, November 29, 2007.
128. “Identifying Bio-Markers of Optimal Embryo Quality”, Bay Area Reproductive Endocrine Society, San Francisco, CA, December 17, 2007.
129. “Contemporary Prevention of Pelvic Adhesions”, Grand Rounds, St. John’s Mercy Hospital, St. Louis, MO, March 26, 2008
130. “Update on the Medical and Surgical Management of Endometriosis”, Ft. Worth OB/GYN Society Meeting, Ft. Worth, TX, April 28, 2008
131. “Prevention of Pelvic Adhesions”, Advances in Women’s Health, Dearborn, MI, September 5, 2008.
132. “Prevention of Pelvic Adhesions”, Advances in Women’s Health, New York, NY, October 3, 2008.
133. “Diagnosis and Treatment of Endometriosis”, Advances in Women’s Health, San Diego, CA, October 14, 2008.
134. “Optimizing Progesterone Support in Fertility Treatment”, Miami OB/GYN Society, Miami, FL, April 1, 2009.
135. “Optimizing Progesterone Support in Fertility Treatment”, Pacific Coast Reproductive Society, Palm Springs, CA, April 24, 2009
136. “Embryo Biomarkers and Their Use in IVF”, Los Angeles Reproductive Endocrine Society Meeting, Santa Monica, CA. June 9, 2009.

137. "Prevention of Pelvic Adhesions", Southwest Fertility Forum, Austin, TX, August 1, 2009.
138. "Optimizing Progesterone Support in Fertility Treatment", Colorado Springs, CO, November 2, 2009.
139. "Optimizing Progesterone Support in Fertility Treatment", Pacific Coast Reproductive Society, Palm Springs, CA, April 15, 2010.
140. "Assessing and Improving Endometrial Competency", SMART ART, Las Vegas, NV, August 5, 2010.
141. "From Mono-ovulation to Ovarian Hyperstimulation: Let's Understand Normal before we make it Better". SMART ART, Las Vegas, NV, August 5, 2010
142. "Cost Effective Diagnosis of Infertility", Annual Meeting of the Georgia OB/GYN Society, Sea Island, GA, August 26-29, 2010.
143. "Pelvic Adhesions: An Ounce of Prevention is Worth a Ton of Cure", Annual Meeting of the Georgia OB/GYN Society, Sea Island, GA, August 26-29, 2010.
144. "Latest Advances in Stimulation of the Poor Responder", Annual meeting of the Midwest Reproductive Society, Chicago, IL. May 9, 2011.
145. "Optimizing Endometrial Competency in IVF", Annual meeting of the Midwest Reproductive Society, Chicago, IL. May 9, 2011
146. "Physiology of Assisted Reproductive Technologies:", START ART, Las Vegas, NV, August 4, 2011.
147. "Optimizing Progesterone Support in Fertility Treatment", Phoenix OB/GYN Society, Phoenix, AZ, September 8, 2011.
148. "Optimizing Progesterone Support in Fertility Treatment", Dallas Area Reproductive Endocrine Society, Dallas, TX, November 9, 2011.
149. "Optimizing Progesterone Support in Fertility Treatment", Nationwide Webinar Programs, New York, NY, November 8, 2011.
150. "Embryo Biomarkers and their potential use in IVF", WNBC New York, January 26, 2012.
151. "Advances in In Vitro Fertilization", Dr. Carol Radio Show, February 8, 2012.

152. “The Role of IM vs. Vaginal Progesterone in ART: IVF and Replacement Cycles”,
Debate at the 68th Annual Meeting of the American Society for Reproductive Medicine, San
Diego, CA. October, 2012.